Previous 10 | Next 10 |
RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans Movantik® included as preferred brand with no restrictions on a National Formulary of one of America's largest payors as of Ju...
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antivir...
RedHill Biopharma (RDHL) announces the presentation of positive Phase 2 safety and efficacy data for oral opaganib in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum ((WMF)) 2021.Shares up marginally during premarket trading.Data showed that, 86.4% of patien...
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum ...
RedHill Biopharma to Present at the BIO Digital International Convention PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , June 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical compan...
RedHill Biopharma (RDHL) announces that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib in patients hospitalized with severe COVID-19 pneumonia.Opaganib has showed positive safety and efficacy signals in preliminary top-line data fr...
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a l...
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Summer Solstice - Best Ideas fro...
RedHill Biopharma Ltd. (RDHL) Q1 2021 Earnings Conference Call May 27, 2021, 8:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Micha Ben-Chorin - Chief Financial Officer Rick Scruggs - Chief C...
RedHill Biopharma (RDHL) saw its Q1 net loss narrow 6% to $22.9M as prescription volumes for its marketed drugs rose.The company beat on EPS but missed on revenues.New prescriptions of Movantik (naloxegol) for opioid-induced constipation increased 4% compared to the year-ago period.In Fe...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...